Novel biomarkers discovery from minimal amount of liquid biopsies for early and precise diagnosis, prognosis and continuous host responses monitoring
Location: Switzerland, Zurich
Employees: 1-10
Total raised: $166.56K
Founded date: 2022
Investors 2
| Date | Name | Website |
| 27.12.2022 | Venture Ki... | venturekic... |
| 25.03.2024 | VentureLab | venturelab... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.12.2024 | - | $166.56K | Venture Ki... |
Mentions in press and media 11
| Date | Title | Description |
| 12.01.2026 | Life sciences and cleantech startups compete for CHF 100,000 | The Ypsomed Foundation has been organizing the Ypsomed innovation Award since 2007, aiming to encourage innovative and entrepreneurial teams from universities and universities of applied sciences from the Swiss Central Plateau to integrate... |
| 22.08.2025 | DayOne Accelerator reveals latest cohort | The DayOne Accelerator is a three-month hybrid program for high-potential, early-stage techbio and healthtech ventures working at the intersection with Pharma R&D. Following the program revamp this year, the program coordinators are no... |
| 30.12.2024 | EVIIVE: Pioneering Precision Diagnostics in Cancer Immunotherapy | In the world of cancer treatment, immunotherapy stands as a beacon of hope. Yet, like a lighthouse in a storm, its effectiveness is often obscured. Less than half of patients respond to these treatments, particularly in aggressive cancers l... |
| 27.12.2024 | EVIIVE gets CHF 150,000 from Venture Kick to develop precision diagnostics for immunotherapy treatment selection | Immunotherapy has revolutionized cancer care, but its success remains inconsistent: less than 50% of patients respond to treatment for many types of cancer, including melanoma and lung, head, and neck cancers. This is largely due to the lac... |
| 27.12.2024 | CHF 150,000 from Venture Kick to bring precision diagnostics to cancer immunotherapies | Immunotherapy has revolutionized cancer care, but its success remains inconsistent: less than 50% of patients respond to treatment for many types of cancer, including melanoma and lung, head, and neck cancers. This is largely due to the la... |
| 18.06.2024 | Borobotics comes out on top at >>venture>> | The Audimax in the main building of ETH Zurich was packed as the awards of the >>venture>> competition were presented yesterday evening. 18 finalists were nominated in six verticals. In addition, six start-ups competed for the ... |
| 18.06.2024 | Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients | Ymmunobio and EVIIVE collaborate to develop an innovative liquid biopsy using extracellular vesicles, enhancing precision in disease detection and monitoring. RIEHEN, SWITZERLAND, June 18, 2024 /EINPresswire.com/ -- Ymmunobio and EVIIVE are... |
| 15.05.2024 | TOP 18 startups contest further for the >>venture>> Award | On June 17, 2024 >>venture>> will host the finale of its annual startup competition at the Audi Max (HG F 30) in the Main Building of ETH Zurich. The ceremony aims to award early-stage startups with innovative solutions in six ... |
| 04.04.2024 | The top 15 startups in de Vigier Award revealed | More than 200 candidates applied for the 2024 W.A de Vigier Award, one of the most important competitions in the Swiss startup ecosystem, and only 50 made it to the shortlist. During the selection Day on February 28, the jury nominated the... |
| 27.03.2024 | Ten startups on a business voyage in Boston | Selected from over 70 applications by a jury of investors and biotech experts, the ten startups selected for the 18th edition of Venture Leaders Biotech will join the roadshow in Boston, one of the world's most important life science hubs.... |
Show more